Oragenics, Inc. (OGEN)

1.0501 +0.0301 (+2.95%) At close: 03:11PM EDT

Oragenics, Inc.

4902 Eisenhower Boulevard
Suite 125
Tampa, FL 33634
United States
813 286 7900
https://www.oragenics.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 5

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Charles L. Pope CPA	Executive Chairman	112.5k	N/A	1952
Mr. Joseph Michael Redmond	President & Interim Principal Executive Officer	N/A	N/A	1961
Ms. Janet Huffman	CFO, Secretary & Treasurer	314.9k	N/A	1972
Dr. James P. Kelly M.A., M.D.	Chief Medical Officer & Member of Scientific Advisor	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Oragenics, Inc., a development-stage company, engages in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases in the United States. Its lead product is ONP-002, a fully synthetic, non-naturally occurring neurosteroid which is lipophilic and can cross the blood-brain barrier to reduce swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplification. The company also develops NT-CoV2-1, a SARS-CoV-2 vaccine product candidate; and Lantibiotic Product Candidate, such as Mutacin 1140 (MU1140), a molecule belonging to the novel class of antibiotics. It has a license agreement with Inspirevax Inc. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Tampa, Florida.

Corporate governance

Oragenics, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.